Cipher Pharmaceuticals Inc.

Equities

CPH

CA17253X1050

Pharmaceuticals

Market Closed - Toronto S.E. 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
8.51 CAD -3.41% Intraday chart for Cipher Pharmaceuticals Inc. -3.51% +53.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cipher Pharmaceuticals Q4 Profit Falls 61% on Charges MT
Cipher Pharmaceuticals Brief: Q4 Net income and earnings per common share were US$7.7 million and $0.32, respectively MT
Cipher Pharmaceuticals Brief: Q4 Total revenue was US$4.9 million, consistent with Q4 2022 MT
Cipher Pharmaceuticals Upgraded to Buy at Stifel GMP; Price Target Raised to C$8.00 MT
Cipher Pharmaceuticals Brief: Announcing that its common shares are now trading on the OTCQX Best Market MT
Cipher Pharmaceuticals Announced Normal Course Issuer Bid MT
Cipher Pharmaceuticals Brief: Announcing Normal Course Issuer Bid MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for 1,337,195 shares, representing 5.57% of its issued share capital. CI
Cipher Pharmaceuticals Inc. authorizes a Buyback Plan. CI
Cipher Pharmaceuticals Seeks Acquisitions CI
Transcript : Cipher Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 10, 2023
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 19, 2022. CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cipher Pharmaceuticals Announced Final Results of Substantial Issuer Bid MT
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 5, 2023. CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 5, 2023, has closed with 1,290,321 shares, representing 5.1% for CAD 6 million. CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 19, 2022, has expired with 284,843 shares, representing 1.13% for CAD 1.03 million. CI
Cipher Pharmaceuticals Plans Substantial Issuer Bid MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for CAD 6 million worth of its shares. CI
Cipher Pharmaceuticals Brief: Announcing Intention to Commence Substantial Issuer Bid, Aggregate Price up to C$6 Million MT
Cipher Pharmaceuticals Inc.authorizes a Buyback Plan. CI
Cipher Pharmaceuticals Seeks M&A CI
Chart Cipher Pharmaceuticals Inc.
More charts
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.51 CAD
Average target price
7.617 CAD
Spread / Average Target
-10.50%
Consensus
  1. Stock Market
  2. Equities
  3. CPH Stock
  4. News Cipher Pharmaceuticals Inc.
  5. Cipher Pharmaceuticals Reports Strong Third Quarter Results, Highlighted by US$1.09 in Cash Per Share